2. Search Result
Search Result
Results for "

BALB/cAJcl mice

" in MedChemExpress (MCE) Product Catalog:

2657

Inhibitors & Agonists

1

Screening Libraries

18

Fluorescent Dye

29

Biochemical Assay Reagents

193

Peptides

1

MCE Kits

94

Inhibitory Antibodies

416

Natural
Products

79

Isotope-Labeled Compounds

1

Antibodies

14

Click Chemistry

36

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-169120
    FKB04

    		Telomerase Cancer
    FKB04 is a telomeric repeat binding factor 2 (TRF2) inhibitor that exerts its antitumor activity by disrupting the telomere maintenance mechanism in liver cancer cells, leading to T-loop defects, telomere shortening, and cellular senescence. Additionally, FKB04 can inhibit tumor growth in a human liver cancer xenograft mouse model (with Huh-7 cells implanted in BALB/c mice). FKB04 can be used in liver cancer research .
    FKB04
  • HY-146496
    Antitubercular agent-20

    		Bacterial Infection
    Antitubercular agent-20 (Compound 2d) is an orally active antitubercular agent. Antitubercular agent-20 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-20 has low cytotoxicity and good tolerance in BALB/c mice .
    Antitubercular agent-20
  • HY-146495
    Antitubercular agent-19

    		Bacterial Infection
    Antitubercular agent-19 (Compound 1c) is an antitubercular agent. Antitubercular agent-19 shows excellent activity against MTB H37Rv and MDR-MTB strains (MIC: ＜0.016 µg/ml). Antitubercular agent-19 shows low cytotoxicity and relatively high acute lethal toxicity in BALB/c mice .
    Antitubercular agent-19
  • HY-169928
    WRN inhibitor 14

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 14 (compound S35) is an orally active WRN inhibitor with anticancer activity. WRN inhibitor 14 results in tumor growth inhibition in the SW48 xenograft model in BALB/c nude mice .
    WRN inhibitor 14
  • HY-161065
    HKI12134085

    		Bacterial Infection
    HKI12134085 (compound 3) is an orally available antibacterial nitrobenzothiazinone (BTZ) derivative with activity against Mycobacterium tuberculosis. HKI12134085 has in vivo inhibitory potency in a BALB/c mouse model of Mycobacterium tuberculosis infection .
    HKI12134085
  • HY-170933
    SGK1-IN-6

    		SGK Cancer
    SGK1-IN-6 (compound 12f) is a potent SGK1 inhibitor with an IC50 of 0.39 μM. SGK1-IN-6 suppresses tumor growth in the PC3 xenograft model in BALB/c nude mice without inducing any observable toxicity .
    SGK1-IN-6
  • HY-170773
    Mtb-IN-9

    		Bacterial Infection
    Mtb-IN-9 (Compound M1) is a specific Mtb inhibitor that inhibits MtbFadD32 and MtbFadD28 activity. Mtb-IN-9 curtails the Mtb survival in infected macrophages and reduces Mtb burden and tubercular granulomas in a chronic infection model of BALB/c mice. Mtb-IN-9 is promising for research of tuberculosis .
    Mtb-IN-9
  • HY-146505
    Tubulin polymerization-IN-6

    		Microtubule/Tubulin Apoptosis Reactive Oxygen Species (ROS) Cancer
    Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor, with an IC50 of 1.09 μM. Tubulin polymerization-IN-6 inhibits cell migration and tube formation and contributes to the anti-angiogenesis. Tubulin polymerization-IN-6 can greatly inhibit tumor growth on HT29 xenograft Balb/c nude mice .
    Tubulin polymerization-IN-6
  • HY-N14910
    Actiketal

    		Antibiotic Bacterial Infection
    Actiketal is a glutarimide antibiotic that inhibits the incorporation of [ 3H]thymidine into EGF-stimulated Balb/MK cells .
    Actiketal
  • HY-N15180
    Corynantheidine

    (-)-Corynantheidine

    		 Opioid Receptor Neurological Disease
    Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice .
    Corynantheidine
  • HY-137440A
    Firazorexton hydrate

    TAK-994

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton hydrate (TAK-994) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton hydrate can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton hydrate
  • HY-120872
    AJS1669 free acid

    		Glycosyltransferase Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-N10346A
    Gluconapin

    		Endogenous Metabolite Cancer
    Gluconapin is a precursor of sulforaphane, a potent anticancer isothiocyanate. Gluconapin reduces the increase in plasma triglycerides induced by corn oil in mice .
    Gluconapin
  • HY-113878
    12-OAHSA

    		Endogenous Metabolite Metabolic Disease
    12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice .
    12-OAHSA
  • HY-138842
    DDN

    		Insulin Receptor Akt ERK Metabolic Disease
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
    DDN
  • HY-137440
    Firazorexton

    TAK-994 free base

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton
  • HY-153617
    FOXO1-IN-3

    		FOXO Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-162396
    P-gp inhibitor 21

    		P-glycoprotein Cancer
    P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .
    P-gp inhibitor 21
  • HY-126426
    CBHcy

    		DNA Methyltransferase Cardiovascular Disease
    CBHcy is an inhibitor for betaine-homocysteine S-methyltransferase (BGMT), with an IC50 of 0.09 μM. CBHcy upregulates the plasma total homocysteine and causes transient hyperhomocysteinemia in mice model .
    CBHcy
  • HY-123237
    KRC-108

    		c-Met/HGFR FLT3 Trk Receptor Apoptosis Autophagy Cancer
    KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice .
    KRC-108
  • HY-P3134
    CPN-267

    		Neuromedin U Receptor (NMUR) Metabolic Disease
    CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC50 of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity .
    CPN-267
  • HY-129661
    AH 7959

    		Opioid Receptor Neurological Disease
    AH 7959 is an orally active N-substituted cyclohexyl methyl benzamide compound that has analgesic effects, the oral and subcutaneous ED50 of AH 7959 in mice is greater than 100 mg/kg .
    AH 7959
  • HY-P6053
    KK-103

    		Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .
    KK-103
  • HY-P991595
    HB-0017

    		Interleukin Related Inflammation/Immunology
    HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
    HB-0017
  • HY-168365
    (±)-Pellotine hydrochloride

    		Drug Isomer Neurological Disease
    (±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .
    (±)-Pellotine hydrochloride
  • HY-169421
    Nav1.7-IN-18

    		Sodium Channel Cancer
    Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, showing analgesic effects in transgenic mice with inherited erythromelalgia (IEM) .
    Nav1.7-IN-18
  • HY-N15182
    4-Trehalosamine

    		Bacterial Drug Derivative Infection
    4-Trehalosamine is a derivative of trehalose with weak antibacterial activity. 4-Trehalosamine shows no toxic effects when injected intravenously into mice at a dose of 625 mg/kg .
    4-Trehalosamine
  • HY-N5190
    Enamidonin

    		Antibiotic Bacterial Infection
    Enamidonin is a lipopeptide antibiotic. Enamidonin inhibits EGF-dependent [ 3H] thymidine involvement in Balb/MK cells (IC50 is 10 μg/mL), and it can restore the deformed SRCTS-NRK form to the normal flat form (ED50 is 10 μg/mL). No antimicrobial activity .
    Enamidonin
  • HY-110197
    6bK TFA
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
    6bK TFA
  • HY-162683
    (S)-PHA533533

    		CDK Neurological Disease Cancer
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .
    (S)-PHA533533
  • HY-P1434
    [Pro3]-GIP (mouse)

    		Insulin Receptor Metabolic Disease
    [Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes .
    [Pro3]-GIP (mouse)
  • HY-165484
    AVP-13358

    		Interleukin Related Inflammation/Immunology
    AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .
    AVP-13358
  • HY-159972
    PKR1 antagonist 1

    		G Protein-coupled Receptor Kinase (GRK) Neurological Disease
    PKR1 antagonist 1 (PC1) is a potent PKR1 antagonist. PKR1 antagonist 1 reduces hyperalgesia and allodynia in SNI mice .
    PKR1 antagonist 1
  • HY-125721
    Tetranactin

    		Fungal Bacterial Antibiotic Infection
    Tetranactin is an orally active antibiotic that has insecticidal properties and can inhibit the growth of Gram-positive bacteria and plant pathogenic fungal in vitro. Tetranactin LD50 for intraperitoneal injection in mice is greater than 300 mg/kg, and the LD50 is greater than 15,000 mg/kg .
    Tetranactin
  • HY-129762
    Yoshi-864

    NSC-102627

    		 DNA/RNA Synthesis Cancer
    Yoshi-864 (NSC-102627) is an alkylsulfonate DNA crosslinker with anticancer activity. Yoshi-864 extends markedly the survival times of mice bearing L1210 leukemia or Ehrlich ascites carcinoma. Yoshi-864 also has a persistent reduction in ability to synthesize DNA in tumor cells from mice bearing the Ehrlich tumor .
    Yoshi-864
  • HY-131334
    AMPK activator 4

    		AMPK Metabolic Disease
    AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
    AMPK activator 4
  • HY-174381
    BChE-IN-41

    		Cholinesterase (ChE) Amyloid-β Tau Protein Neurological Disease
    BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC50 =12 nM, Ki = 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ1-42 .
    BChE-IN-41
  • HY-114853
    BVT.13

    		PPAR Metabolic Disease
    BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386). In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice .
    BVT.13
  • HY-163087
    PT-91

    		Orphan Receptor Neurological Disease Metabolic Disease
    PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice .
    PT-91
  • HY-168629
    FXR agonist 9

    		FXR Metabolic Disease
    FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC50 of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl4(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .
    FXR agonist 9
  • HY-147548
    Keap1-Nrf2-IN-10

    		Reactive Oxygen Species (ROS) Quinone Reductase Others
    Keap1-Nrf2-IN-10 (compound 15) is a potent NQO1 inducer. Keap1-Nrf2-IN-10 inhibits oxidative stress by decreasing the levels of MDA, ROS, NQO1 in the liver for gamma-irradiated mice. Keap1-Nrf2-IN-10 improves the survival of gamma-irradiated mice .
    Keap1-Nrf2-IN-10
  • HY-176127
    JX10

    		p38 MAPK NF-κB Metabolic Disease
    JX10 is a senomorphic agent. JX10 suppresses the expression of p38 MAPK and NF-κB. JX10 exhibits competent antiaging effects in C. elegans, senescent cells, and aged mice .
    JX10
  • HY-P990215
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1)

    		Interleukin Related Infection Inflammation/Immunology
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1) is a mouse-derived anti-mouse IL-27 p28 IgG2a, κ type antibody inhibitor. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) can neutralize IL-27. Anti-Mouse IL-27 p28 Antibody (MM27.7B1) delays CD8+ T cell reconstitution mediated by IL-27 after murine anti-thymocyte globulin (mATG) treatment in BALB/c heart allografts mice models .
    Anti-Mouse IL-27 p28 Antibody (MM27.7B1)
  • HY-173517
    NHE-1-IN-2

    		Na+/H+ Exchanger (NHE) Neurological Disease
    NHE-1-IN-2 (compound 7g) is a potent NHE-1 inhibitor with an IC50 of 0.78 μM. NHE-1-IN-2 alleviates left ventricular systolic dysfunction in mice model of heart failure .
    NHE-1-IN-2
  • HY-158311
    Anti-osteoporosis agent-8

    		RANKL/RANK p38 MAPK NF-κB Endocrinology
    Anti-osteoporosis agent-8 (Compound 4aa) is an inhibitor for RANKL, which inhibits RANKL-induced osteoclastogenesis and osteoclast differentiation (IC50 is 2.41 μM) in cells RAW264.7. Anti-osteoporosis agent-8 ameliorates bone loss in an ovariectomized (OVX) mice model .
    Anti-osteoporosis agent-8
  • HY-157430
    BET-IN-21

    		Epigenetic Reader Domain Neurological Disease
    BET-IN-21 (compound 16) is a blood-brain barrier-permeable extra terminal domain (BET) inhibitor with the Ki of 230 nM. BET-IN-21 inhibits microglia activation and has ameliorative effects on experimental autoimmune encephalomyelitis mice .
    BET-IN-21
  • HY-W008151
    Diphenyl Phosphate

    		Mitochondrial Metabolism Metabolic Disease
    Diphenyl Phosphate inhibits growth and energy metabolism in zebrafish and mice in a sex-specific manner. Diphenyl Phosphate can inhibit the activity of SDH (respiratory complex II), reduce the expression of CPT1 and disrupts the integrity of the mitochondrial membrane. Diphenyl Phosphate may be used in research on metabolic diseases .
    Diphenyl Phosphate
  • HY-12995
    BI 665915

    		FLAP Cardiovascular Disease Inflammation/Immunology
    BI 665915 is an orally active and potent 5-lipoxygenase-activating protein (FLAP) inhibitor. BI 665915 inhibits FLAP production that blocks LTB4 biosynthesis in mice. BI 665915 is promising for research of various inflammatory diseases, including respiratory and cardiovascular diseases .
    BI 665915
  • HY-100827
    Safotibant

    LF22-0542

    		 Bradykinin Receptor Inflammation/Immunology
    Safotibant (LF22-0542) is a selective antagonist for kinin B1 receptor (BKB1R), with Ki of 0.35 and 6.5 nM, for human and mouse BKB1R, respectively. Safotibant exhibits analgesic and anti-inflammatory property in mice model .
    Safotibant
  • HY-138669
    C004019

    		PROTACs Tau Protein Neurological Disease
    C004019 is a BBB-penetrable and small-molecule PROTAC that targets tau. C004019 can simultaneously recruit tau and E3 ligase, and effectively clear tau proteins by promoting the ubiquitination and proteasome-dependent degradation of tau, thereby improving synaptic and cognitive functions in Alzheimer's disease (AD) mice. C004019 can be used in the research of AD and tau protein-related diseases. (Pink: Ligand for target protein (HY-138679); Black: linker (HY-140189); Blue: E3 Ligase Ligand (HY-138678))
    C004019

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: